TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Hcy level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: IBT (In-Breast Tumor Recurrence)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Cumulative rates of distant metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Biochemical failure rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: mean time interval between entry to delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk for severe maternal infections
Endpoint domain: Adverse events/effects
Primary endpoint: Expression levels of ATPase 6, BMP15, and NAIP genes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wake-up time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of awakening
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction of MMAs in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction of total blood arsenic
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum ACH-induced forearm blood flow (FBF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: FSH usage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: hMG usage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Positive treatment response maintenance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Switch rate into mania
Endpoint domain: Adverse events/effects
Primary endpoint: Cumulative incidence of death, reinfarction, stroke, or TVR
Endpoint domain: Mortality/survival
Primary endpoint: frequency of intervention
Endpoint domain: Adverse events/effects
Primary endpoint: frequency of tachysystole
Endpoint domain: Adverse events/effects
Primary endpoint: frequency of hyperstimulation
Endpoint domain: Adverse events/effects
Primary endpoint: Intraoperative ischemic episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Postoperative bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Average time to complete suturing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Wound healing index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean gingival recession reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mode of delivery preferences
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Actual mode of delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual analogue scale ratings
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Overall survival of GCA patients compared to controls
Endpoint domain: Mortality/survival
Primary endpoint: Overall symptom levels at final assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean fecal and fluid tagging scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean interpretation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Blood neutrophil CD11b mean fluorescent intensity levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Blood neutrophil numbers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: BAL neutrophil numbers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction in metabolism in the medial frontal cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cortisol habituation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: ipsilateral stroke or ipsilateral stroke death within 30 days
Endpoint domain: Mortality/survival
Primary endpoint: Risk of VT colonization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Colonization density with VT strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Risk of NVT colonization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence of major complications
Endpoint domain: Mortality/survival
Primary endpoint: Endotracheal intubation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean CST decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of analgesics taken
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Days alive and off broad-spectrum antibiotics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delta MODS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mechanical ventilation days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Lean Mass (LM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of braces
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose-limiting side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Mean maximum tolerable daily dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in area of secondary hyperalgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean mitochondrial diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight gain prevention criteria (BW change within ±3 %)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of children with antipolyribosylribitol phosphate ≥0.15 μg/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage with human complement serum bactericidal activity ≥1:8 for meningococcal serogroup C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage with human complement serum bactericidal activity ≥1:8 for serogroup Y
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reliability of ULCs in echocardiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Risk of Acute Myocardial Infarction (AMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Emergence of extrapyramidal symptoms (EPS)
Endpoint domain: Adverse events/effects
Primary endpoint: Discontinuation due to EPS
Endpoint domain: Adverse events/effects
Primary endpoint: QFT-GIT intra-assay concordance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient preference for MF
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Compliance prediction with preferred drug
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: mean apparent oral clearance of quinine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean area under the plasma concentration versus time curve (AUC) of 3‐hydroxyquinine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive Trendelenburg test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HHS, OHS, and EQ-5D scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: LAV (Left Atrial Volume)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LAVI (Left Atrial Volume Index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in non-HDL cholesterol (non-HDL-C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Blood Lead Levels (BLLs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Severity of RLS-6 scale symptoms during the night
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Curve deterioration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degenerative disc changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: midterm all-cause mortality
Endpoint domain: Mortality/survival
Primary endpoint: Primary outcome events
Endpoint domain: Mortality/survival
Primary endpoint: Hospitalization for heart failure
Endpoint domain: Adverse events/effects
Primary endpoint: Hospitalization for unstable angina
Endpoint domain: Adverse events/effects
Primary endpoint: Pain intensity during the first postoperative hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: quality-adjusted life month survival time
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: mean capillary erythrocyte velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Direct cost savings per patient with IDDM
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Direct cost savings per patient with NIDDM
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Aggregate health care cost savings
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time to final prosthesis insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sPLA(2) concentration reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fasting concentrations of GH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Fasting concentrations of IGF-I
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Basal and pulsatile GH secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Percentage of patients reaching target blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Average systolic blood pressure reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Average diastolic blood pressure reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Back complaints
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Two-year local control (LFFS)
Endpoint domain: Mortality/survival
Primary endpoint: Outfield intrahepatic control (OutFFS)
Endpoint domain: Mortality/survival
Primary endpoint: No respiratory reaction during aspirin desensitization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Urinary leukotriene E4 (LTE4) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of antimicrobial prescribing according to guidelines
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: continence rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in subjective symptoms related to orthostatic hypotension (OH)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Decrease in blood pressure after L‐DOPS treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Shortest distance of the interspinous processes (ISP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Time of first bowel sound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentages distribution of lymphocyte
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentages distribution of neutrophil
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in level of hard exudates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: joint displacements after cyclic loading
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: displacement to failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximal lower and upper body strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: psychosocial distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: number of chair stands
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: up-and-go time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: zBMI reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: average daily pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ≥ 30% reduction in pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glasgow dyspepsia severity (Gladys) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health Status Short Form 12 (SF12)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Ulcer healing drug (UHD) costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Opinions on cadaveric transplantation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: incidence of infant BMI z‐score ≥90th centile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: electromyographic fatigue
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Increase in ferritin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achieving target Hb
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Baseline IGF-1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Baseline TSH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: clinical remission rate (CDAI <150)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD-related hospitalisations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Providers' preference for counseling
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Providers' report of sufficient time for counseling
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Patients' computer skills and Internet access
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: global well-being
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: DAS28-3 score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aphasia Quotient change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Subjective appreciation of clinical performance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reasons for transport
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reasons for transport
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reasons for transport
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: rate of patient mortality
Endpoint domain: Mortality/survival
Primary endpoint: number of organ dysfunctions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median duration of grade ≧2 mucositis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anterior knee laxity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anterior kneeling pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood glucose lowering effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Insulin secretion increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean serum Na+ values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum osmolality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: recurrent dysphagia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: need for redilation sessions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Duration of peripheral intravenous catheterization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of attempts for catheterization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: First stick success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Global outcome improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: 1-grade improvement in glabellar line severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of relapse
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of depression, anxiety, and PTSD-related symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Continuous abstinence rates weeks 9‐12 (CAR9‐12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 7-day point prevalence abstinence at end of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative recovery rates of the external limiting membrane
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: External limiting membrane recovery period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal systolic blood pressure change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximal diastolic blood pressure change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Intraejaculatory Latency Time (IELT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of improvement in premature ejaculation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Normalization of serum 25(OH)D levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of cleaved embryos
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maturation rates of GV oocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of chromosomal abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of fecal fat excreted
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Concentrations of total DAG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Post-void residual urine volume (PVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: OABSS urgency urinary incontinence (UUI) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SCL‐90 DEP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SCL‐90 ANX
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VABS‐II score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rapid RFSP (>0.2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute CD4 T cell counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Viral load (VL) at week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: tinnitus score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: completely lysed cusps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incompletely lysed cusps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of focal hypovascular hepatic lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Patient satisfaction with the discussion
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient anxiety level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Patient trust level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time to breastfeeding cessation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early breastfeeding cessation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: phospho-STAT6 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: diuresis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes